Pradaxa (dabigatran etexilate) is the first oral direct thrombin inhibitor, indicated for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip or knee replacement surgery.


After oral administration, dabigatran etexilate is rapidly absorbed and converted to its active form dabigatran, which inhibits both free and clot-bound thrombin.

Thrombin enables the conversion of fibrinogen to fibrin during the coagulation cascade; its inhibition prevents the development of thrombus

In two phase III studies,1,2 once-daily oral dabigatran was non-inferior to subcutaneous enoxaparin once daily in the prevention of venous thromboembolism (VTE) and all-cause mortality in patients undergoing major joint replacement surgery. Both treatments had a similar safety profile.

In one of the studies,1 once-daily dabigatran was given for 6–10 days after total knee replacement surgery. In the other study,2 involving patients undergoing hip replacement surgery, treatment was continued for 28–35 days


1. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007: 5; 2178–2185.
2. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous
thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007: 370; 949–56.

View Pradaxa drug record

Further information: Boehringer

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases